BACKGROUND: Some studies suggest that schizophrenia may be associated with an increased risk of diabetes, independently of antipsychotic medications and other confounding factors. Previous studies have also suggested that there is an increased prevalence of diabetes in the relatives of schizophrenia probands. METHOD: First-degree siblings of schizophrenia probands (N=6) and control subjects (N=12) were administered a glucose tolerance test. Subjects were matched for gender, age, body mass index, neighborhood of residence, socio-economic status and smoking habits. RESULTS: The siblings of schizophrenia probands had a significantly increased two-hour mean glucose concentration compared to the control subjects (respective means [SD] were 100.5 mg/dL [27.7] vs. 78.0 [12.3]; p<0.03). Baseline glucose concentrations did not differ. CONCLUSIONS: Although confirmation with larger samples is needed, these results and other studies suggest that diabetes may share familial risk factors with schizophrenia.
BACKGROUND: Some studies suggest that schizophrenia may be associated with an increased risk of diabetes, independently of antipsychotic medications and other confounding factors. Previous studies have also suggested that there is an increased prevalence of diabetes in the relatives of schizophrenia probands. METHOD: First-degree siblings of schizophrenia probands (N=6) and control subjects (N=12) were administered a glucose tolerance test. Subjects were matched for gender, age, body mass index, neighborhood of residence, socio-economic status and smoking habits. RESULTS: The siblings of schizophrenia probands had a significantly increased two-hour mean glucose concentration compared to the control subjects (respective means [SD] were 100.5 mg/dL [27.7] vs. 78.0 [12.3]; p<0.03). Baseline glucose concentrations did not differ. CONCLUSIONS: Although confirmation with larger samples is needed, these results and other studies suggest that diabetes may share familial risk factors with schizophrenia.
Authors: Emilio Fernandez-Egea; Brian Miller; Miguel Bernardo; Thomas Donner; Brian Kirkpatrick Journal: Schizophr Res Date: 2007-11-26 Impact factor: 4.939
Authors: S D Rosenberg; R E Drake; G L Wolford; K T Mueser; T E Oxman; R M Vidaver; K L Carrieri; R Luckoor Journal: Am J Psychiatry Date: 1998-02 Impact factor: 18.112
Authors: C M Gilvarry; P C Sham; P B Jones; M Cannon; P Wright; S W Lewis; P Bebbington; B K Toone; R M Murray Journal: Schizophr Res Date: 1996-03 Impact factor: 4.939
Authors: Tony A Cohn; Gary Remington; Robert B Zipursky; Azar Azad; Philip Connolly; Thomas M S Wolever Journal: Can J Psychiatry Date: 2006-05 Impact factor: 4.356
Authors: Emilio Fernandez-Egea; Clemente García-Rizo; Brian Miller; Eduard Parellada; Azucena Justicia; Miguel Bernardo; Brian Kirkpatrick Journal: Psychosom Med Date: 2011-09-23 Impact factor: 4.312
Authors: Suraj Sarvode Mothi; Neeraj Tandon; Jaya Padmanabhan; Ian T Mathew; Brett Clementz; Carol Tamminga; Godfrey Pearlson; John Sweeney; Matcheri S Keshavan Journal: Schizophr Res Date: 2015-04-19 Impact factor: 4.939
Authors: Anne Marie Greenhalgh; Leticia Gonzalez-Blanco; Clemente Garcia-Rizo; Emilio Fernandez-Egea; Brian Miller; Miguel Bernardo Arroyo; Brian Kirkpatrick Journal: Schizophr Res Date: 2016-10-17 Impact factor: 4.939
Authors: Johann Steiner; Aye Mu Myint; Kolja Schiltz; Sabine Westphal; Hans-Gert Bernstein; Martin Walter; Matthias L Schroeter; Markus J Schwarz; Bernhard Bogerts Journal: Cardiovasc Psychiatry Neurol Date: 2010-06-10